Frontiers
US$ 20.89
glp-1 drugs pharmaceutical companies news 2025 health pharma today obesity october Outlook for obesity in 2025: more GLP-1 Receptor Agonist Market Size
Description
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E
Providers pay particular attention to indicators of inflammation, signs of insulin resistance, and hormone-related symptoms associated with conditions like PCOS, menopause, or autoimmune disorders
Clinical trials have revealed that retatrutide can reduce markers of inflammation, such as C-reactive protein (CRP), which are associated with an increased risk of cardiovascular disease
Hermansen K, Kipnes M, Luo E, et al
The most cost-effective approach may be a combination strategy
